Altimmune (ALT) Slides 2.7% as Market Volatility Hits Clinical-Stage Biopharma
Altimmune (ALT) dips 2.7% as its 31% monthly decline deepens—trading below its 200‑day SMA at $2.12. Learn why early‑stage biopharma faces volatility.
2 minutes to read
ALTIMMUNE INC
Altimmune Shares Drop 3% to $2.17, Near 12‑Month Low – What Investors Need to Know
Altimmune’s share drops 3%, hitting a one‑year low, as investors await new clinical data amid valuation pressures in peptide‑based therapeutics.
2 minutes to read
Altimmune (ALT) Rises 3.14% to $2.23 Amid Bearish Trend—What It Means for Investors
Altimmune (ALT) gains 3.14% to $2.23, but remains below its 200‑day MA; investors watch regulatory milestones and peer momentum for future upside.
3 minutes to read
Altimmune Shares Rise 1.36% as New Pemvidutide Data Boosts MASH & Alcohol‑Liver Prospects
Altimmune’s latest data shows pemvidutide improving liver fibrosis and inflammation in Phase‑2b MASH patients, sparking a Phase‑3 trial and strong stock movement.
2 minutes to read